The accompanying notes are an integral part of these consolidated financial statements.
The accompanying notes are an integral part of these consolidated financial statements.
The accompanying notes are an integral part of these consolidated financial statements.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOVEMBER 30, 2018 and 2017
NOTE 1
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business.
Cryo-Cell International, Inc. (the Company or Cryo-Cell) was incorporated in Delaware on September 11, 1989 and is
headquartered in Oldsmar, Florida. The Company is organized in three reportable segments, cellular processing and cryogenic cellular storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use,
the manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells and cellular processing, and cryogenic storage of umbilical cord blood stem cells for public use. Revenues recognized for the cellular
processing and cryogenic cellular storage represent sales of the umbilical cord blood stem cells program to customers and income from licensees selling the umbilical cord blood stem cells program to customers outside the United States. Revenues
recognized for the manufacture of PrepaCyte CB units represent sales of the PrepaCyte CB units to customers. Revenue recognized for the cryogenic storage of umbilical cord blood stem cells for public use is generated from the sale of the cord blood
units to the National Marrow Donor Program (NMDP), which distributes the cord blood units to transplant centers located in the United States and around the world. The Companys headquarters facility in Oldsmar, Florida handles all
aspects of its U.S.-based business operations including the processing and storage of specimens, including specimens obtained from certain of its licensees customers. The specimens are stored in commercially available cryogenic storage
equipment.
On October 10, 2001, Saneron Therapeutics, Inc. merged into one of the Companys wholly owned subsidiaries, CCEL
Bio-Therapies,
Inc. (CCBT), which then changed its name to Saneron CCEL Therapeutics, Inc. (SCTI or Saneron). As part of the merger, the Company contributed 260,000 shares of its
common stock, whose fair value was $1,924,000 and 195,000 common shares of another of its subsidiaries, Stem Cell Preservation Technologies, Inc., whose fair value was $3,900. At the conclusion of the merger, the Company retained a 43.42%
non-controlling
interest in the voting stock of SCTI. As of November 30, 2018 and 2017, the Company had an interest of approximately 33% in the voting stock of SCTI. The accompanying consolidated financial
statements as of November 30, 2018 and 2017 reflect the investment in SCTI under the equity method of accounting.
Basis of Presentation
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America.
The accompanying consolidated financial statements as of November 30, 2018 and November 30, 2017 and for the
years then ended includes the accounts of the Company and all of its subsidiaries, which are inactive. All intercompany balances have been eliminated upon consolidation.
Concentration of Risks
Financial
instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Deposit Insurance Corporation (FDIC) limit. The Company
places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk. The Company may from time to
34
time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC). The Company
believes these are conservative investments with a low risk for any loss of principal. The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate.
The Company depends on one supplier for the source of its collection kits, a critical component of the umbilical cord blood stem cell
collection process. However, the Company believes that alternative sources of supply are available.
The Company depends on three
suppliers for the supply and manufacturing of the PrepaCyte CB units. However, the Company believes that alternative sources of supply and manufacturing are available.
The Company depends on one third party, the National Marrow Donor Program, to manage the public umbilical cord stem cells that are needed for
transplant.
During fiscal 2018 and 2017, there were no concentration of risks.
Use of Estimates
The preparation of
consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition
Revenue
Recognition for Arrangements with Multiple Deliverables
For multi-element arrangements, the Company allocates revenue to all
deliverables based on their relative selling prices. In such circumstances, accounting principles establish a hierarchy to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective
evidence of fair value (VSOE), (ii) third-party evidence of selling price (TPE), and (iii) best estimate of the selling price (ESP). VSOE generally exists only when the Company sells the deliverable
separately and it is the price actually charged by the Company for that deliverable.
The Company has identified two deliverables
generally contained in the arrangements involving the sale of its umbilical cord blood product. The first deliverable is the processing of a specimen. The second deliverable is either the annual storage of a specimen, the
18-year
or
21-year
storage fee charged for a specimen or the life-time storage fee charged for a specimen. The Company has allocated revenue between these deliverables using
the relative selling price method. The Company has VSOE for its annual storage fees as the Company renews storage fees annually with its customers on a stand-alone basis. Because the Company has neither VSOE nor TPE for the processing,
18-year
or
21-year
storage and life-time storage deliverables, the allocation of revenue has been based on the Companys ESPs. Amounts allocated to processing a specimen
are recognized at the time the processing of the specimen is complete. Amounts allocated to the storage of a specimen are recognized ratably over the contractual storage period. Any discounts given to the customer are recognized by applying the
relative selling price method whereby after the Company determines the selling price to be allocated to each deliverable (processing and storage), the sum of the prices of the deliverables is then compared to the arrangement consideration, and any
difference is applied to the separate deliverables ratably.
35
The Companys process for determining its ESP for deliverables without VSOE or TPE considers
multiple factors that may vary depending upon the unique facts and circumstances related to each deliverable. Key factors considered by the Company in developing the ESPs for its processing,
21-year
storage
and life-time storage fee include the Companys historical pricing practices, as well as expected profit margins.
The Company
records revenue from processing and storage of specimens and pursuant to agreements with licensees. The Company recognizes revenue from processing fees upon completion of processing and recognizes storage fees ratably over the contractual storage
period as well as other income from royalties paid by licensees related to long-term storage contracts which the Company has under license agreements. Contracted storage periods are annual,
twenty-one
years
and lifetime. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the annual storage fee, the
twenty-one-year
storage fee and the
life-time storage fee that is being recognized over the contractual storage period as well as royalties received from foreign licensees related to long-term storage contracts in which the Company has future obligations under the license agreement.
The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12 months. The Company also records revenue within processing and storage fees from shipping and handling billed to customers
when earned. Shipping and handling costs that the Company incurs are expensed and included in cost of sales.
The Company records revenue
from the sale of the PrepaCyte CB product line upon shipment of the product to the Companys customers.
The Company records revenue
for the Public Cord Blood Bank from the sales of cord blood stem cell units upon shipment. The Company sells and provides units not likely to be of therapeutic use for research to qualified organizations and companies operating under Institutional
Review Board approval. The Company recognizes revenue upon delivery of the unit.
Revenue Sharing Agreements
The Company entered into Revenue Sharing Agreements (RSAs) prior to 2002 with various third and related parties. The Companys
RSAs provide that in exchange for a
non-refundable
up-front
payment, the Company would share for the duration of the contract a percentage of its future storage revenue
collected from the annual storage fees charged related to a certain number of specimens that originated from specific geographical areas. The RSAs have no definitive term or termination provisions. The sharing applies to the storage fees collected
for all specified specimens in the area up to the number covered in the contract. When the number of specimens is filled, any additional specimens stored in that area are not subject to revenue sharing. As there are empty spaces resulting from
attrition, the Company agrees to fill them as soon as possible. The Company has reflected these
up-front
payments as long-term liabilities on the accompanying consolidated balance sheets. The Company does not
intend to enter into additional RSAs.
In the future, the Company could reverse the liability relating to the RSAs over an appropriate
period of time, based on the Companys expectations of the total amount of payments it expects to pay to the other party under the particular RSA. However, the RSAs do not establish a finite term or time frame over which to estimate the total
payments and the Company had not previously estimated and has concluded that it is not currently practicable to estimate the projected cash flows under the RSAs. At present, the Company intends to defer the reversal of the liability, until such time
as these amounts can be
36
determined. During the periods when the Company defers the reversal of the liability, the quarterly payments made during these periods will be treated as interest expense, which will be
recognized as the payments become due. In future periods, if a portion of the liability can be
de-recognized
based on the effective interest method, the payments will be allocated between interest and
amortization of the liability. As cash is paid out to the other party during any period, the liability would be
de-recognized
based on the portion of the total anticipated payouts made during the period, using
the effective interest method. That is, a portion of the payment would be recorded as interest expense, and the remainder would be treated as repayment of principal, which would reduce the liability.
License and Royalty Agreements
The
Company has entered into licensing agreements with certain investors in various international markets in an attempt to capitalize on the Companys technology. The investors typically pay a licensing fee to receive Company marketing programs,
technology and
know-how
in a selected area. The investor may be given a right to sell
sub-license
agreements as well. As part of the accounting for the
up-front
license fee paid, or payable, to the Company, revenue from the
up-front
license fee is recognized based on such factors as when the payment is due, collectability and
when all material services or conditions relating to the sale have been substantially performed by the Company based on the terms of the agreement. The Company has twelve active licensing agreements. The following areas each have one license
agreement: El Salvador, Guatemala, Panama, Honduras, China and Pakistan. The following areas each have two license agreements: India, Nicaragua and Costa Rica.
In addition to the license fee, the Company earns processing and storage fees on subsequent processing and storage revenues received by the
licensee in the licensed territory and a fee on any
sub-license
agreements that are sold by the licensee where applicable. These fees are included in processing and storage fees revenue on the consolidated
statements of comprehensive income (loss). As part of the accounting for royalty revenue from India, the Company uses estimates and judgments based on historical processing and storage volume in determining the timing and amount of royalty revenue
to recognize. The Company periodically reviews license and royalty receivables for collectability and, if necessary, will record an expense for an allowance for uncollectible accounts.
Cash and Cash Equivalents
Cash and cash
equivalents consist of highly liquid investments with a maturity date of three months or less at the time of purchase.
Accounts Receivable
Accounts receivable consist of uncollateralized amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell
processing and storage programs and amounts due from license affiliates, and sublicensee territories. Accounts receivable are due within 30 days and are stated at amounts net of an allowance for doubtful accounts. Accounts outstanding longer than
the contractual payment terms are considered past due. The Company determines its allowance by considering the length of time accounts receivable are past due, the Companys previous loss history, and the clients current ability to pay
its obligations. Therefore, if the financial condition of the Companys clients were to deteriorate beyond the estimates, the Company may have to increase the allowance for doubtful accounts which could have a negative impact on earnings. The
Company
writes-off
accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.
37
Inventory
As part of the Asset Purchase Agreement, (see Note 2), the Company has an agreement with Duke University (Duke) expiring on
January 31, 2020 for Duke to receive, process, and store cord blood units for the Public Cord Blood Bank (Duke Services). As of November 30, 2018, the Company had approximately 6,000 cord blood units in inventory. These units
are valued at the lower of cost or net realizable value. Costs include the cost of collecting, transporting, processing and storing the unit. Costs charged by Duke for their Duke Services are based on a monthly fixed fee for storing 12 blood units
per month. The Company computes the cost per unit for these Duke Services and capitalizes the unit cost on all blood units shipped and stored in a year at Duke. If the Company ships and stores less than 144 blood units with Duke in a
one-year
period, a portion of these fixed costs are expensed and included in facility operating costs. Certain costs of collection incurred, such as the cost of collection staff and transportation costs incurred to
ship Public Bank units from hospitals to the stem cell laboratory are allocated to banked units based on an average cost method. Costs incurred related to cord blood units that cannot be sold are expensed in the period incurred and are included in
facility operating costs in the accompanying statements of operations. The Company records a reserve against inventory for units which have been processed and frozen but may not ultimately become distributable (see Note 3).
Property and Equipment
Property and
equipment are stated at cost. Depreciation is provided primarily by the straight-line method over the estimated useful lives of the related assets. Estimated useful lives of property and equipment are as follows:
|
|
|
Furniture and equipment
|
|
3-10
years
|
Leasehold improvements
|
|
Lesser of
8-10
years or the lives of the leases
|
Computer software internal use
|
|
1-5
years
|
Leasehold improvements are amortized over the shorter of the respective life of the lease or the estimated
useful lives of the improvements. Upon the sale or retirement of depreciable assets, the cost and related accumulated depreciation is removed from the accounts and the resulting profit or loss is reflected in earnings. Expenditures for maintenance,
repairs and minor betterments are expensed as incurred.
The Company capitalizes external direct costs of materials and services consumed
in developing or obtaining
internal-use
computer software. Capitalized
internal-use
software costs, which are included in property and equipment, are depreciated over
the estimated useful lives of the software.
Long-Lived Assets
The Company evaluates the realizability of its long-lived assets, which requires impairment losses to be recorded on long-lived assets used in
operations when indicators of impairment, such as reductions in demand or when significant economic slowdowns are present. Reviews are performed to determine whether the carrying value of an asset is impaired, based on comparisons to undiscounted
expected future cash flows. If this comparison indicates that there is impairment and carrying value is in excess of fair value, the impaired asset is written down to fair value, which is typically calculated using: (i) quoted market prices or
(ii) discounted expected future cash flows utilizing a discount rate. The Company did not note any impairment as of November 30, 2018 and November 30, 2017, respectively.
38
Goodwill
Goodwill represents the excess of the purchase price of the assets acquired from Cord:Use (Note 2) over the estimated fair value of the net
tangible, intangible and identifiable assets acquired. The annual assessment of the reporting unit is performed as of September 1st, and an assessment is performed at other times if an event occurs or circumstances change that would more likely than
not reduce the fair value of the asset below its carrying value. Step one of the impairment assessment compares the fair value of the reporting unit to its carrying value and if the fair value exceeds its carrying value, goodwill is not impaired. If
the carrying value exceeds the fair value, the implied fair value of goodwill is compared to the carrying value of goodwill. If the implied fair value exceeds the carrying value then goodwill is not impaired; otherwise, an impairment loss would be
recorded by the amount the carrying value exceeds the implied fair value. As of November 30, 2018, and November 30, 2017, goodwill, is reflected on the consolidated balance sheets at $1,941,411 and $0.
Income Taxes
Deferred income tax assets
and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and
liabilities are measured using enacted tax rates expected to be recovered or settled. The Company records a valuation allowance when it is more likely than not that all of the future income tax benefits will not be realized. When the
Company changes its determination as to the amount of deferred income tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to income tax expense in the period in which such determination is made. The
ultimate realization of the Companys deferred income tax assets depends upon generating sufficient taxable income prior to the expiration of the tax attributes. In assessing the need for a valuation allowance, the Company projects future
levels of taxable income. This assessment requires significant judgment. The Company examines the evidence related to the recent history of losses, the economic conditions in which the Company operates and forecasts and projections to make that
determination.
The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax
authority would more likely than not sustain the position following an audit. For tax positions meeting the
more-likely-than-not
threshold, the amount recognized in the financial statements is the largest
benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from managements belief that a position
can or cannot be sustained upon examination based on subsequent information or potential lapse of the applicable statute of limitation for certain tax positions.
The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. For fiscal 2018 and 2017 the Company
had no uncertain tax provisions and therefore no material provisions for interest or penalties related to uncertain tax positions.
Research,
Development and Related Engineering Costs
Research, development and related engineering costs are expensed as incurred.
Cost of Sales
Cost of sales represents
the associated expenses resulting from the processing, testing, storage and delivery of the umbilical cord blood. Cost of sales related to PrepaCyte CB represents the associated expenses resulting from the manufacturing of the PrepaCyte CB units.
Cost of sales related to the Public Cord Blood Bank represents the associated expenses resulting from the collection, shipping, processing and storage of the cord blood stem cell units.
39
Advertising
Advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the accompanying consolidated
statements of comprehensive (loss) income. Total advertising expense for the fiscal years ended November 30, 2018 and 2017 was approximately $986,664 and $1,008,000, respectively.
Rent Expense
Rent is expensed on a
straight-line basis over the term of the lease and is included in cost of sales and selling, general and administrative expenses in the accompanying consolidated statements of comprehensive (loss) income. All leases include provisions for
escalations and related costs.
Legal Expense
Legal fees are expensed as incurred and are included in selling, general and administrative expenses in the accompanying consolidated
statements of comprehensive (loss) income.
Fair Value of Financial Instruments
Management uses a fair value hierarchy, which gives the highest priority to quoted prices in active markets. The fair value of financial
instruments is estimated based on market trading information, where available. Absent published market values for an instrument or other assets, management uses observable market data to arrive at its estimates of fair value. Management believes
that the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of these instruments. The Company believes that the fair value of its Revenue
Sharing Agreements (RSA) liability recorded on the balance sheet is between the recorded book value and up to the Companys previous settlement experience, due to the various terms and conditions associated with each RSA.
The Company uses an accounting standard that defines fair value as an exit price, representing the amount that would be received to sell an
asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use
in pricing an asset or liability. As a basis for considering such assumptions, the standard establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The three levels of inputs used to measure fair value
are as follows:
|
|
|
|
|
Level 1
|
|
Quoted prices in active markets for identical assets or liabilities.
|
|
|
Level 2
|
|
Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not
active; or other inputs that are observable or can be corroborated by observable market data.
|
|
|
Level 3
|
|
Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar
techniques that use significant unobservable inputs.
|
The following table summarizes our financial assets and liabilities measured at fair value on a recurring
basis as of November 30, 2018 and 2017, respectively, segregated among the appropriate levels within the fair value hierarchy:
40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements
|
|
|
|
Fair Value at
|
|
|
at November 30, 2018 Using
|
|
Description
|
|
November 30,
2018
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trading securities
|
|
$
|
68,816
|
|
|
$
|
68,816
|
|
|
|
|
|
|
|
|
|
Available-for-sale
securities
|
|
|
806,873
|
|
|
|
806,873
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
875,689
|
|
|
$
|
875,689
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent consideration
|
|
$
|
4,282,975
|
|
|
$
|
|
|
|
|
|
|
|
$
|
4,282,975
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
4,282,975
|
|
|
$
|
|
|
|
|
|
|
|
$
|
4,282,975
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent Consideration:
|
|
|
|
|
|
|
|
|
Beginning Balance as of
November 30, 2017
|
|
$
|
|
|
|
|
|
|
Additions Cord:Use earnout
|
|
|
4,698,255
|
|
|
|
|
|
Fair value adjustment as of November 30, 2018
|
|
|
(415,280
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending balance as of
November 30, 2018
|
|
$
|
4,282,975
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements
|
|
|
|
Fair Value at
|
|
|
at November 30, 2017 Using
|
|
Description
|
|
November 30,
2017
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trading securities
|
|
$
|
96,600
|
|
|
$
|
96,600
|
|
|
|
|
|
|
|
|
|
Available-for-sale
securities
|
|
|
342,722
|
|
|
|
342,722
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
439,322
|
|
|
$
|
439,322
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following is a description of the valuation techniques used for these items, as well as the general classification of such
items pursuant to the fair value hierarchy:
Trading securities
Fair values for these investments are based on quoted prices
of identical securities in active markets and are therefore classified within Level 1 of the fair value hierarchy. For trading securities, there was approximately ($28,000) and ($82,000) in unrealized holding losses,
respectively, recorded in other income and expense on the accompanying consolidated statements of comprehensive (loss) income for the twelve months ended November 30, 2018 and 2017.
41
Available-for-sale
securities
These investments
are classified as available for sale and consist of marketable equity securities that we intend to hold for an indefinite period of time. Investments are stated at fair value and unrealized holding gains and losses are reported as a component of
accumulated other comprehensive income until realized. Realized gains or losses on disposition of investments are computed using the first in, first out (FIFO) method and reported as income or loss in the period of disposition in the accompanying
consolidated statements of comprehensive (loss) income. For
available-for-sale
securities, there was approximately $300,000 and $6,000 in unrealized holding gains
(loss), net of tax, respectively, reported as comprehensive income on the accompanying statements of comprehensive (loss) income for the years ended November 30, 2018 and 2017.
Contingent consideration -
The contingent consideration is the earnout that Cord:Use is entitled to from the Companys sale of the
public cord blood inventory from and after closing. See Note 2. The estimated fair value of the contingent earnout was determined using a monte carlo analysis examining the frequency and mean value of the resulting earnout payments. The resulting
value captures the risk associated with the form of the payout structure. The risk-neutral method is applied, resulting in a value that captures the risk associated with the form of the payout structure and the projection risk. The carrying amount
of the liability may fluctuate significantly and actual amounts paid may be materially different from the estimated value of the liability.
Product
Warranty and Cryo-Cell Cares
TM
Program
In December 2005, the Company began
providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate
family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June 1, 2017, the
Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell Cares
TM
program, the Company will
pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients
who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. The Company does not maintain
insurance for this warranty program and therefore maintains reserves to cover any estimated potential liabilities. The Companys reserve balance is based on the $75,000 or $50,000 (as applicable) maximum payment and the $10,000 maximum expense
reimbursement multiplied by formulas to determine the projected number of units requiring a payout. The Company determined the estimated expected usage and engraftment failure rates based on an analysis of the historical usage and failure rates and
the historical usage and failure rates in other private and public cord blood banks based on published data. The Companys estimates of expected usage and engraftment failure could change as a result of changes in actual usage rates or failure
rates and such changes would require an adjustment to the established reserves. The historical usage and failure rates have been very low and a small increase in the number of transplants or engraftment failures could cause a significant increase in
the estimated rates used in determining the Companys reserve. In addition, the reserve will increase as additional umbilical cord blood specimens are stored which are subject to the warranty. As of November 30, 2018 and November 30,
2017 the Company recorded reserves under these programs in the amounts of approximately $18,000 and $18,000, respectively, which are included in accrued expenses in the accompanying consolidated balance sheets.
42
(Loss) Income per Common Share
Basic (loss) income per common share was computed by dividing net income by the weighted average number of common shares outstanding for the
fiscal year ended or as of the date indicated. Diluted income per common share includes the effect of all dilutive stock options. The composition of basic and diluted net (loss) income per share is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
November 30, 2018
|
|
|
|
November 30, 2017
|
|
Numerator:
|
|
|
|
|
|
|
|
|
Net (loss) income
|
|
($
|
855,000
|
)
|
|
$
|
2,315,000
|
|
Denominator:
|
|
|
|
|
|
|
|
|
Weighted-average shares outstanding-basic
|
|
|
7,463,051
|
|
|
|
7,062,870
|
|
Dilutive common shares issuable upon exercise of stock options
|
|
|
|
|
|
|
590,114
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares-diluted
|
|
|
7,463,051
|
|
|
|
7,652,984
|
|
|
|
|
|
|
|
|
|
|
(Loss) Income per share:
|
|
|
|
|
|
|
|
|
Basic
|
|
($
|
0.11
|
)
|
|
$
|
0.33
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
($
|
0.11
|
)
|
|
$
|
0.30
|
|
|
|
|
|
|
|
|
|
|
For the year ended November 30, 2018, the Company excluded the effect of all outstanding stock options
from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.
For the year ended November 30, 2017, the Company excluded the effect of 22,500 stock options from the computation of diluted earnings
per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.
Stock Compensation
As of November 30, 2018, the Company has two stock-based employee compensation plans, which are described in Note 11 to the consolidated
financial statements. The Companys stock-based employee compensation plan became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting. The Company recognized
approximately $478,000 and $972,000 for the fiscal years ended November 30, 2018 and November 30, 2017, respectively, of stock compensation expense. The Company reversed $444,000 of stock compensation expense during the twelve months ended
November 30, 2018 as the
Co-CEOs
each opted to receive a lump sum cash payment in lieu of 30,000 shares of earned common stock pursuant to the terms of their Employment Agreements. The reversal had no
impact on the accompanying consolidated statements of comprehensive (loss) income as other compensation expense was recognized to offset the reversal.
The Company recognizes stock-based compensation based on the fair value of the related awards. Under the fair value recognition guidance of
stock-based compensation accounting rules, stock-based compensation expense is estimated at the grant date based on the fair value of the award and is recognized as expense over the requisite service period of the award. The fair value of
service-based vesting condition and performance-based vesting condition stock option awards is determined using the Black-Scholes valuation model. For stock option awards with only service-based vesting conditions and graded vesting features, the
Company recognizes stock compensation expense based on the graded-vesting method. To value awards with market-based vesting conditions the Company uses a binomial valuation model. The
43
Company recognizes compensation cost for awards with market-based vesting conditions on a graded-vesting basis over the derived service period calculated by the binomial valuation model. The use
of these valuation models involves assumptions that are judgmental and highly sensitive in the determination of compensation expense and include the expected life of the option, stock price volatility, risk-free interest rate, dividend yield,
exercise price, and forfeiture rate. Forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period.
The estimation of stock awards that will ultimately vest requires judgment and to the extent that actual results or updated estimates differ
from current estimates, such amounts will be recorded as a cumulative adjustment in the period they become known. The Company considered many factors when estimating forfeitures, including the recipient groups and historical experience. Actual
results and future changes in estimates may differ substantially from current estimates.
The Company issues performance-based equity
awards which vest upon the achievement of certain financial performance goals, including revenue and income targets. Determining the appropriate amount to expense based on the anticipated achievement of the stated goals requires judgment, including
forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the required performance targets and adjustments are made as appropriate. The cumulative impact
of any revision is reflected in the period of the change. If the financial performance goals are not met, the award does not vest, so no compensation cost is recognized and any previously stock-recognized stock-based compensation expense is
reversed.
The Company issues equity awards with market-based vesting conditions which vest upon the achievement of certain stock price
targets. If the awards are forfeited prior to the completion of the derived service period, any recognized compensation is reversed. If the awards are forfeited after the completion of the derived service period, the compensation cost is not
reversed, even if the awards never vest.
Recently Issued Accounting Pronouncements
In August 2018, the FASB issued Accounting Standards Update
No. 2018-15,
Intangibles
Goodwill and Other
Internal-Use
Software (Topic
350-40):
Customers Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service
Contract.
This update addresses how a customer should account for the costs of implementing a cloud computing service arrangement (also referred to as a hosting arrangement). Entities should account for costs associated with
implementing a cloud computing arrangement that is considered a service contract in the same way as accounting for implementation costs incurred to develop or obtain software for internal use using the guidance in Topic
350-40.
The amendments address when costs should be capitalized rather than expensed, the term to use when amortizing capitalized costs, and how to evaluate the unamortized portion of these capitalized
implementation costs for impairment. The ASU also includes guidance on how to present implementation costs in the financial statements and creates additional disclosure requirements. The guidance is effective for annual periods beginning after
December 15, 2019, and interim periods within that reporting period. The Company is currently evaluating the effect that the updated standard will have on our financial statements.
In June 2018, the FASB issued Accounting Standards Update
No. 2018-07,
Compensation
Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.
This update simplifies the accounting for nonemployee share-based payment transactions by expanding the scope of Topic 718, Compensation-Stock
Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is effective for annual periods beginning after December 15, 2018, and interim periods within that reporting period. The
Company is currently evaluating the effect that the updated standard will have on our financial statements.
44
In February 2018, the FASB issued Accounting Standards Update
No. 2018-02
, Income Statement Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income
. This update relates to the
impacts of the tax legislation commonly referred to as the Tax Cuts and Jobs Act (the Act). The guidance permits the reclassification of certain income tax effects of the Act from Other Comprehensive Income to Retained Earnings (stranded
tax effects). The guidance also requires certain new disclosures. The guidance is effective for annual periods beginning after December 15, 2018, and interim periods within that reporting period. Early adoption is permitted. Entities may adopt
the guidance using one of two transition methods; retrospective to each period (or periods) in which the income tax effects of the Act related to the items remaining in Other Comprehensive Income are recognized or at the beginning of the period of
adoption. The Company is currently evaluating the impact that the guidance may have on its Consolidated Financial Statements.
In May
2017, the FASB issued Accounting Standards Update
No. 2017-09,
Compensation Stock Compensation (Topic 718): Scope of Modification Accounting.
This update provides clarity, reduces the
diversity in practice, and the cost and complexity when applying the guidance in Topic 718 to a change to the terms or conditions of a share-based payment award. The new standard is effective for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2017, although early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on our financial statements.
In January 2017, the FASB issued Accounting Standards Update
No. 2017-04,
Intangibles
Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment
. The update removes Step 2 from the goodwill impairment test. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2019, although early adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on our financial statements.
In December 2016, the FASB issued Accounting Standards Update
No. 2016-18,
Statement of Cash
Flows (Topic 230). Restricted Cash
. This update clarifies how entities should present restricted cash and restricted cash equivalents in the statement of cash flows. The new guidance requires a reconciliation of totals in the statement of cash
flows to the related cash and cash equivalents and restricted cash captions in the balance sheet. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2017 with early adoption
permitted. The Company is currently evaluating the effect that the updated standard will have on our financial statements.
In August
2016, the FASB issued Accounting Standards Update
No. 2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.
This update addresses eight specific
cash flow issues with the objective of reducing the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2017. The Company is currently evaluating the effect that the updated standard will have on our financial statements.
45
In June 2016, the FASB issued Accounting Standards Update
No. 2016-13,
Financial Instruments Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
. This update provides financial statement users with more decision-useful
information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss
impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The new standard is effective for
fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently evaluating the effect that the updated standard will have on our financial statements.
In May 2014, the FASB issued Accounting Standards Update
No.2014-09,
Revenue
from Contracts with
Customers,
which sets forth a single, comprehensive revenue recognition model for all contracts with customers to improve comparability. Subsequently, the FASB issued several standards related to ASU
2014-09
(collectively, the New Revenue Standard). The New Revenue Standard requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the
consideration that the entity expects to receive in exchange for those goods or services. The New Revenue Standard also requires expanded disclosures. Entities have the choice to apply these the New Revenue Standard retrospectively to each reporting
period presented or recognize the cumulative effect of applying these standards at the date of the initial application and not adjust comparative information.
The Companys implementation plan utilized a phased project plan. The Company gained an understanding of the New Revenue Standard and its
potential impact on our revenue streams and contracts within those revenue streams. The Company then performed a detailed review of our historical revenue recognition policies and contracts to assess the potential impacts the New Revenue Standard
may have on previously reported and future revenues. The Company is finalizing its assessment but has not identified any accounting changes that would materially affect the amount of the Companys reported revenues. The Company, however,
expects to capitalize incremental contract acquisition costs related to sales commissions and amortize the costs over the expected benefit period of the customer relationship.
The Company plans to adopt the standard using the modified retrospective method, which will apply the rules to contracts that are incomplete
as of December 1, 2018. At transition, the Company will estimate the contract acquisition costs that should be capitalized and make an immaterial adjustment to retained earnings reflecting the cumulative impact for the accounting changes
related to the adoption of the New Revenue Standard. The Company will complete the implementation of the New Revenue Standard and disclose the required information in the Companys
10-Q
for the first
quarter of fiscal year 2019.
In February 2016, the FASB issued Accounting Standards Update
No. 2016-02,
Leases (Topic 842).
This update requires organizations that lease assets with lease terms of more than 12 months to recognize assets and liabilities for the rights and obligations
created by those leases on their balance sheets. It also requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from
leases. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect that the updated standard
will have on its consolidated balance sheets and related disclosures.
In January 2016, the FASB issued Accounting Standards Update
No. 2016-01,
Financial InstrumentsOverall (Subtopic
825-10):
Recognition and Measurement of Financial Assets and Financial Liabilities.
This update requires
all equity investments to be measured at fair value with changes in fair value recognized in net income, requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability
resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments, and eliminates the requirement for public entities
to disclose the methods and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet. The new standard is effective for fiscal years beginning
after December 15, 2017, including interim periods within those fiscal years. Early adoption is
46
permitted for the accounting guidance on financial liabilities under the fair value option. The impact of the new standard for the Company will be that equity securities with a readily
determinable fair value will no longer be classified as available for sale securities. The changes in fair value of these securities will be included in income from operations rather than comprehensive income on the Companys financial
statements.
Note 2 Acquisition
On June 11, 2018, Cryo-Cell completed its acquisition of substantially all of the assets (the Cord Purchase) of Cord:Use Cord
Blood Bank, Inc., a Florida corporation (Cord:Use), in accordance with the definitive Asset Purchase Agreement between Cryo-Cell and Cord:Use (the Purchase Agreement), including without limitation Cord:Uses inventory of
public cord blood units existing as of the closing date (the Public Cord Blood Inventory) and Cord:Uses shares of common stock of Tianhe Stem Cell Biotechnologies, Inc., an Illinois corporation (the Tianhe Capital
Stock). Cord:Use was in the business of public and private cord blood and tissue, collection, processing, storage and banking.
The
aggregate consideration payable at closing under the Purchase Agreement was $14,000,000, with $10,500,000 paid in cash and the balance paid through the delivery to Seller of 465,426 shares of Cryo-Cells common stock, par value $0.01 per share
(Common Stock), at $7.52 per share. In addition, Cryo-Cell assumed certain limited liabilities incurred by Cord:Use in connection with its business that were unpaid as of the closing date and that directly relate to the services to be
provided after closing by Cryo-Cell. Cryo-Cell also assumed certain of Cord:Uses contracts and the obligations arising therefrom after the closing.
Additionally, Cord:Use is entitled to an earnout from Cryo-Cells sale of the public cord blood inventory from and after closing. Each
calendar year after the closing, Cryo-Cell will pay to Cord:Use 75% of all gross revenues, net of any returns, received from the sale of public cord blood inventory in excess of $500,000. Such payments will be made quarterly, within 30 days of the
end of the last month of each calendar quarter, until the public cord blood inventory is exhausted. In addition, each calendar year after closing, until the public cord blood inventory is exhausted, for every $500,000 of retained gross revenues, net
of any returns, received and retained by Cryo-Cell in excess of the initial $500,000 retained by Cryo-Cell during such year, Cryo-Cell will deliver $200,000 worth of Cryo-Cell Common stock to Cord:Use, up to an aggregate value of $5,000,000.
Cord:Use is also entitled to a portion of the gross profits generated, or deemed to have been generated, by Cryo-Cell from its ownership of the Tianhe Capital Stock.
The Company incurred $580,000 in costs associated with the acquisition of Cord:Use.
The following summarizes the fair value of the consideration of the Acquisition as of the purchase date:
|
|
|
|
|
Consideration
|
|
|
|
Cash
|
|
$
|
10,500,000
|
|
Cryo-Cell common stock
|
|
|
3,500,000
|
|
Cord blood inventory earnout
|
|
|
4,698,255
|
|
|
|
|
|
|
Consideration
|
|
$
|
18,698,255
|
|
|
|
|
|
|
The following summarizes the preliminary allocation of the total purchase price for the Acquisition:
|
|
|
|
|
Accounts receivable
|
|
$
|
188,019
|
|
Inventory
|
|
|
16,037,957
|
|
Prepaid expenses
|
|
|
68,867
|
|
Property and equipment
|
|
|
568,407
|
|
47
|
|
|
|
|
Other assetTiahne capital stock
|
|
|
308,000
|
|
Brand
|
|
|
31,000
|
|
Customer relationships
|
|
|
960,000
|
|
|
|
|
|
|
Total identifiable net assets acquired
|
|
|
18,162,250
|
|
|
|
|
|
|
Less: Deferred revenue
|
|
|
(1,405,406
|
)
|
|
|
|
|
|
Goodwill
|
|
|
1,941,411
|
|
|
|
|
|
|
Total
|
|
$
|
18,698,255
|
|
|
|
|
|
|
The Company has not completed its assignment of goodwill to the segment reporting units. Goodwill includes the
fair value of the assembled workforce. The fair value of the assembled workforce was estimated by applying a cost approach, representing a level 2 measurement. The goodwill is not deductible for income tax purposes.
The property and equipment are stated at an estimate of fair value.
The Tiahne capital stock is an investment that is valued based on fair value. Cord:Use had a supply and equity participation agreement with
Tiahne who is engaged in medical and life science research that involves the use of stem cells derived from umbilical cord blood units in clinical trials for humans.
The fair value of the company brand and customer relationships were estimated by applying an income approach, representing a level 3
measurement. The fair value estimates are based on (1) an assumed discount rate of 19%, (2) long-term sustainable growth rate of 3%, (3) market royalty rate of 1% and (4) one and thirty-year lives for the brand and customer relationships,
respectively.
The fair values of the assets acquired includes public cord blood banking inventory of $16,037,957 which the Company
expects to sell to outside customers. The Company also acquired accounts receivable of $188,019 and prepaid expenses of $68,867.
The fair
values of the customer relationships reflect the anticipated cash flows over their expected lives.
The fair value of deferred revenue is
valued based on the cost method. Deferred revenues are
pre-payment
fees for future storage of umbilical cord blood and/or cord tissue specimens. The short- and long-term deferred revenue is $330,508 and
$1,074,898, respectively.
The valuations are not final and are subject to revision for a period not to exceed
one-year
after the acquisition date as information relative to the acquisition date fair values become available.
Unaudited Pro forma Results
The
following table provides the Companys consolidated unaudited pro forma revenues, net income per basic and diluted common share had the results of the acquired businesses operations been included in its operations commencing on
December 1, 2016, based on available information related to the respective operations. This proforma information presented is not necessarily indicative either of the combined results of operations that actually would have been realized by the
Company had the acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results, and does not account for any operation improvements to be made by the Company post-acquisition.
48
|
|
|
|
|
|
|
|
|
|
|
Twelve months ended November 30,
|
|
|
|
2018
|
|
|
2017
|
|
Revenue
|
|
$
|
31,388,278
|
|
|
$
|
30,649,232
|
|
Net income (loss)
|
|
($
|
2,658,679
|
)
|
|
($
|
1,019,453
|
)
|
Earnings (loss) per share:
|
|
|
|
|
|
|
|
|
Basic
|
|
($
|
0.36
|
)
|
|
($
|
0.14
|
)
|
Diluted
|
|
($
|
0.36
|
)
|
|
($
|
0.14
|
)
|
Note 3 Inventory
Inventory is comprised of public cord blood banking specimens, collection kits, finished goods,
work-in-process
and raw materials. Collection kits are used in the collection and processing of umbilical cord blood and cord tissue stem cells, finished goods include products purchased or assumed for resale
and for the use in the Companys processing and storage service. Inventory in the Public Cord Blood Bank includes finished goods that are specimens that are available for resale. The Company considers inventory in the Public Cord Blood Bank
that has not completed all testing to determine viability to be work in process. The components of inventory at November 30, 2018 and November 30, 2017 are as follows:
|
|
|
|
|
|
|
|
|
|
|
As of November 30, 2018
|
|
|
As of November 30, 2017
|
|
Raw materials
|
|
$
|
|
|
|
$
|
|
|
Work-in-process
|
|
|
188,085
|
|
|
|
97,210
|
|
Work-in-process
Public Bank
|
|
|
|
|
|
|
|
|
Finished goods
|
|
|
5,262
|
|
|
|
210,854
|
|
Finished goods Public Bank
|
|
|
15,831,081
|
|
|
|
|
|
Collection kits
|
|
|
19,163
|
|
|
|
14,220
|
|
Inventory reserve
|
|
|
(7,718
|
)
|
|
|
(7,718
|
)
|
|
|
|
|
|
|
|
|
|
Total inventory
|
|
$
|
16,035,873
|
|
|
$
|
314,566
|
|
|
|
|
|
|
|
|
|
|
Note 4 Intangible Assets
The Company incurs certain legal and related costs in connection with patent and trademark applications. If a future economic benefit is
anticipated from the resulting patent or trademark or an alternate future use is available to the Company, such costs are capitalized and amortized over the expected life of the patent or trademark. The Companys assessment of future economic
benefit involves considerable management judgment. A different conclusion could result in the reduction of the carrying value of these assets.
Intangible assets were as follows as of November 30, 2018 and 2017:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Useful lives
|
|
|
November 30, 2018
|
|
|
November 30, 2017
|
|
Patents
|
|
|
10-20 years
|
|
|
$
|
234,570
|
|
|
$
|
34,570
|
|
Less: Accumulated amortization
|
|
|
|
|
|
|
(23,663
|
)
|
|
|
(11,800
|
)
|
License agreement
|
|
|
10 years
|
|
|
|
470,000
|
|
|
|
470,000
|
|
Less: Intangible asset impairment
|
|
|
|
|
|
|
(185,000
|
)
|
|
|
(185,000
|
)
|
Less: Accumulated amortization
|
|
|
|
|
|
|
(123,528
|
)
|
|
|
(91,861
|
)
|
Customer relationships
Prepacyte
®
CB
|
|
|
15 years
|
|
|
|
41,000
|
|
|
|
41,000
|
|
49
|
|
|
|
|
|
|
|
|
|
|
Less: Intangible asset impairment
|
|
|
|
|
(26,267
|
)
|
|
|
(26,267
|
)
|
Less: Accumulated amortization
|
|
|
|
|
(5,276
|
)
|
|
|
(4,224
|
)
|
Brand
|
|
1 year
|
|
|
31,000
|
|
|
|
|
|
Less: Accumulated amortization
|
|
|
|
|
(15,500
|
)
|
|
|
|
|
Customer relationships Cord:Use
|
|
30 years
|
|
|
960,000
|
|
|
|
|
|
Less: Accumulated amortization
|
|
|
|
|
(16,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Intangible Assets
|
|
$
|
1,341,336
|
|
|
$
|
226,418
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected amortization related to these intangible assets for each of the next five fiscal years and for
periods thereafter is as follows:
Fiscal years ending November 30:
|
|
|
|
|
2019
|
|
$
|
92,081
|
|
2020
|
|
$
|
76,343
|
|
2021
|
|
$
|
76,343
|
|
2022
|
|
$
|
76,343
|
|
2023
|
|
$
|
76,343
|
|
Thereafter
|
|
$
|
943,883
|
|
|
|
|
|
|
Total
|
|
$
|
1,341,336
|
|
|
|
|
|
|
Amortization expense of intangibles was approximately $76,000 and $35,000 for the twelve months ended
November 30, 2018 and November 30, 2017, respectively.
Note 5 Note Payable
On May 20, 2016, the Company entered into a Credit Agreement (Agreement) with Texas Capital Bank, National Association
(TCB) for a term loan of $8.0 million in senior credit facilities. The proceeds of the term loan were used by the Company to fund repurchases of the Companys common stock. Subject to the terms of the Agreement, on May 20,
2016, TCB advanced the Company $100.00. On July 1, 2016, TCB advanced the remaining principal amount of $7,999,900 per a promissory note dated May 20, 2016 between the Company and TCB, at a rate of 3.75% per annum plus LIBOR, payable
monthly with a maturity date of July 2021. On August 26, 2016, the Company entered into a First Amendment to Credit Agreement with TCB. Pursuant to terms of the First Amendment to Credit Agreement, on August 26, 2016, TCB made an
additional advance to the Company in principal amount of $2,133,433 per an Amended and Restated Promissory Note dated August 26, 2016 between the Company and TCB. The additional proceeds of the term loan were used by the Company to fund the
extinguishment of revenue sharing agreements. On June 11, 2018, the Company entered into a Second Amendment to Credit Agreement with TCB. Pursuant to the terms of the Second Amendment to Credit Agreement, TCB increased the current outstanding
principal amount of the loan from TCB by $9,000,000 to finance a portion of the purchase price of the Cord:Use Purchase. In connection therewith, Cryo-Cell executed and delivered to TCB a Second Amended and Restated Promissory Note, in the principal
amount of $15,500,000. As of November 30, 2018, and November 30, 2017, the Company paid interest of $589,583 and $406,139, respectively, which is reflected in interest expense on the accompanying consolidated statements of comprehensive
(loss) income.
50
On May 20, 2016, the Company also entered into a Subordination Agreement with TCB and
CrowdOut Capital LLC (CrowdOut) for a subordinated loan of the principal amount of $650,000, which amount CrowdOut advanced to the Company on May 20, 2016. The proceeds of the subordinated loan were to be used by the Company to fund
continued repurchases of the Companys common stock. Per a promissory note dated May 20, 2016 between the Company and CrowdOut, interest at 12% per annum on the principal sum of $650,000 is payable monthly with a maturity date of July
2021, at which time, the principal amount of $650,000 was payable. On June 5, 2017, the principal sum of $650,000 plus interest of $867 was paid to CrowdOut and the subordinated loan was paid in full. As of November 30, 2018 and
November 30, 2017, the Company paid interest of $0 and $40,300, respectively, which is reflected in interest expense on the accompanying consolidated statements of comprehensive (loss) income.
Collateral of the term and subordinated loans includes all money, securities and property of the Company.
The Company incurred debt issuance costs related to the term and subordinated loans in the amount of $548,085 which is recorded as a direct
reduction of the carrying amount of the note payable and amortized over the life of the loan. As of November 30, 2018, and November 30, 2017, $109,293 and $125,434, respectively, of the debt issuance costs were amortized and are reflected
in interest expense on the accompanying consolidated statements of comprehensive income (loss).
As of November 30, 2018, and
November 30, 2017, the note payable obligation was as follows:
|
|
|
|
|
|
|
|
|
|
|
November 30, 2018
|
|
|
November 30, 2017
|
|
Note payable
|
|
$
|
13,208,433
|
|
|
$
|
7,500,100
|
|
Unamortized debt issuance costs
|
|
|
(264,923
|
)
|
|
|
(204,917
|
)
|
|
|
|
|
|
|
|
|
|
Net note payable
|
|
$
|
12,943,510
|
|
|
$
|
7,295,183
|
|
|
|
|
|
|
|
|
|
|
Current portion of note payable
|
|
$
|
3,100,000
|
|
|
$
|
2,000,000
|
|
Long-term note payable, net of debt issuance costs
|
|
|
9,843,510
|
|
|
|
5,295,183
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
12,943,510
|
|
|
$
|
7,295,183
|
|
|
|
|
|
|
|
|
|
|
Future principal payments under the note payable obligation are as follows:
|
|
|
|
|
Years ending November 30:
|
|
Amount
|
|
2019
|
|
$
|
3,100,000
|
|
2020
|
|
|
3,100,000
|
|
2021
|
|
|
3,100,000
|
|
2022
|
|
|
3,100,000
|
|
2023
|
|
|
808,433
|
|
|
|
|
|
|
Total
|
|
$
|
13,208,433
|
|
|
|
|
|
|
51
Interest expense on the note payable for the years ended November 30, 2018 and
November 30, 2017 was as follows:
|
|
|
|
|
|
|
|
|
|
|
November 30, 2018
|
|
|
November 30, 2017
|
|
Interest expense on notes payable
|
|
$
|
589,583
|
|
|
$
|
446,439
|
|
Debt issuance costs
|
|
|
109,293
|
|
|
|
125,434
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$
|
698,876
|
|
|
$
|
571,873
|
|
|
|
|
|
|
|
|
|
|
Note 6
Segment Reporting
During the third quarter of fiscal 2018, the Company purchased the assets and assumed contracts that Cord:Use used in the operation of its cord
blood business (See Note 2). The Company evaluated and determined that this acquisition qualifies as a separate segment.
The Company is organized in
three reportable segments:
|
1.
|
The cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family
use. Revenue is generated from the initial processing and testing fees and the annual storage fees charged each year for storage (the Umbilical cord blood and cord tissue stem cell service).
|
|
2.
|
The manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem
cells. Revenue is generated from the sales of the PrepaCyte CB units (the PrepaCyte CB).
|
|
3.
|
The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. Revenue is
generated from the sale of the cord blood units to the National Marrow Donor Program (NMDP), which distributes the cord blood units to transplant centers located in the United States, and around the world.
|
The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, income
tax (expense) benefit, other comprehensive loss, and assets for the years ended November 30, 2018 and 2017:
|
|
|
|
|
|
|
|
|
|
|
For the years ended November 30,
|
|
|
|
2018
|
|
|
2017
|
|
Net revenue:
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
28,817,872
|
|
|
$
|
24,942,089
|
|
PrepaCyte CB
|
|
|
104,323
|
|
|
|
442,190
|
|
Public cord blood banking
|
|
|
296,295
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net revenue
|
|
$
|
29,218,490
|
|
|
$
|
25,384,279
|
|
|
|
|
|
|
|
|
|
|
Cost of sales:
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
7,744,208
|
|
|
$
|
6,257,628
|
|
PrepaCyte CB
|
|
|
169,397
|
|
|
|
466,763
|
|
Public cord blood banking
|
|
|
626,057
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
$
|
8,539,662
|
|
|
$
|
6,724,391
|
|
|
|
|
|
|
|
|
|
|
52
|
|
|
|
|
|
|
|
|
Operating profit:
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
5,620,394
|
|
|
$
|
5,067,228
|
|
PrepaCyte CB
|
|
|
(101,329
|
)
|
|
|
(61,002
|
)
|
Public cord blood banking
|
|
|
(329,762
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating profit
|
|
$
|
5,189,303
|
|
|
$
|
5,006,226
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization:
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
281,072
|
|
|
$
|
193,741
|
|
PrepaCyte CB
|
|
|
36,254
|
|
|
|
36,254
|
|
Public cord blood banking
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total depreciation and amortization
|
|
$
|
317,326
|
|
|
$
|
229,995
|
|
|
|
|
|
|
|
|
|
|
Interest expense:
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
1,546,900
|
|
|
$
|
1,302,650
|
|
PrepaCyte CB
|
|
|
|
|
|
|
|
|
Public cord blood banking
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$
|
1,546,900
|
|
|
$
|
1,302,650
|
|
|
|
|
|
|
|
|
|
|
Income tax (expense) benefit:
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
(4,472,504
|
)
|
|
$
|
(1,308,603
|
)
|
PrepaCyte CB
|
|
|
|
|
|
|
|
|
Public cord blood banking
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income tax (expense) benefit
|
|
$
|
(4,472,504
|
)
|
|
$
|
(1,308,603
|
)
|
|
|
|
|
|
|
|
|
|
Other comprehensive (loss) income:
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
300,119
|
|
|
$
|
6,457
|
|
PrepaCyte CB
|
|
|
|
|
|
|
|
|
Public cord blood banking
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other comprehensive income (loss)
|
|
$
|
300,119
|
|
|
$
|
6,457
|
|
|
|
|
|
|
|
|
|
|
The following table shows the assets by segment as of November 30
2018 and November 30, 2017:
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
26,239,260
|
|
|
$
|
23,360,714
|
|
PrepaCyte CB
|
|
|
319,802
|
|
|
|
549,283
|
|
Public cord blood banking
|
|
|
15,831,081
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
42,390,143
|
|
|
$
|
23,909,997
|
|
|
|
|
|
|
|
|
|
|
NOTE
7-
ALLOWANCE FOR DOUBTFUL ACCOUNTS
The activity in the allowance for doubtful accounts is as follows for the years ended November 30, 2018 and 2017:
53
|
|
|
|
|
December 1, 2016
|
|
$
|
2,278,862
|
|
Bad Debt Expense
|
|
|
77,012
|
|
Write-offs
|
|
|
(744,233
|
)
|
Recoveries
|
|
|
487,350
|
|
|
|
|
|
|
November 30, 2017
|
|
|
2,098,991
|
|
Bad Debt Expense
|
|
|
727,483
|
|
Write-offs
|
|
|
(907,263
|
)
|
Recoveries
|
|
|
345,637
|
|
|
|
|
|
|
November 30, 2018
|
|
$
|
2,264,848
|
|
NOTE 8PROPERTY AND EQUIPMENT
The major classes of property and equipment are as follows:
|
|
|
|
|
|
|
|
|
|
|
2018
|
|
|
2017
|
|
Furniture and equipment
|
|
$
|
5,905,910
|
|
|
$
|
5,066,605
|
|
Leasehold improvements
|
|
|
1,200,934
|
|
|
|
1,188,584
|
|
Computer software internal use
|
|
|
1,194,039
|
|
|
|
1,194,039
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,300,883
|
|
|
|
7,449,228
|
|
Less: Accumulated Depreciation
|
|
|
(6,807,482
|
)
|
|
|
(6,566,846
|
)
|
|
|
|
|
|
|
|
|
|
Total Property and Equipment
|
|
$
|
1,493,401
|
|
|
$
|
882,382
|
|
|
|
|
|
|
|
|
|
|
Depreciation expense was approximately $241,000 in fiscal 2018 and approximately $230,000 in fiscal 2017 of
which approximately $137,000 and $98,000 is included in cost of sales, respectively, in the accompanying consolidated statements of comprehensive (loss) income.
NOTE 9ACCRUED EXPENSES
Accrued expenses are as
follows:
|
|
|
|
|
|
|
|
|
|
|
November 30,
|
|
|
|
2018
|
|
|
2017
|
|
Professional fees
|
|
$
|
14,867
|
|
|
$
|
84,555
|
|
Payroll and payroll taxes (1)
|
|
|
1,021,004
|
|
|
|
1,068,381
|
|
Interest expense
|
|
|
864,676
|
|
|
|
648,274
|
|
General expenses
|
|
|
478,449
|
|
|
|
424,782
|
|
Federal and state taxes
|
|
|
323,792
|
|
|
|
356,483
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
2,702,788
|
|
|
$
|
2,582,475
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Payroll and payroll taxes includes accrued vacation and wages due as of November 30, 2018 and
November 30, 2017.
|
54
NOTE 10INCOME TAXES
The Company recorded the following income tax provision for the years ended November 30, 2018 and 2017.
|
|
|
|
|
|
|
|
|
|
|
2018
|
|
|
2017
|
|
Current:
|
|
|
|
|
|
|
|
|
Federal
|
|
$
|
1,467,000
|
|
|
$
|
1,483,000
|
|
State
|
|
|
622,000
|
|
|
|
483,000
|
|
Foreign
|
|
|
108,000
|
|
|
|
108,000
|
|
|
|
|
|
|
|
|
|
|
Subtotal
|
|
|
2,197,000
|
|
|
|
2,074,000
|
|
Deferred:
|
|
|
|
|
|
|
|
|
Federal
|
|
|
2,716,000
|
|
|
|
(318,000
|
)
|
State
|
|
|
(441,000
|
)
|
|
|
(447,000
|
)
|
Foreign
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subtotal
|
|
|
2,275,000
|
|
|
|
(765,000
|
)
|
|
|
|
|
|
|
|
|
|
Income Tax Expense
|
|
$
|
4,472,000
|
|
|
$
|
1,309,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of November 2018 and 2017 the tax effects of temporary differences that give rise to the deferred tax
assets are as follows:
|
|
|
|
|
|
|
|
|
|
|
2018
|
|
|
2017
|
|
Tax Assets:
|
|
|
|
|
|
|
|
|
Deferred income (Net of Discounts)
|
|
$
|
5,157,000
|
|
|
$
|
5,886,000
|
|
Tax over book basis in unconsolidated affiliate
|
|
|
1,214,000
|
|
|
|
1,788,000
|
|
Accrued payroll
|
|
|
257,000
|
|
|
|
405,000
|
|
Reserves and other accruals
|
|
|
868,000
|
|
|
|
1,039,000
|
|
Stock compensation
|
|
|
330,000
|
|
|
|
711,000
|
|
Depreciation and Amortization
|
|
|
428,000
|
|
|
|
618,000
|
|
Transaction costs
|
|
|
18,000
|
|
|
|
0
|
|
RSA
Buy-out
|
|
|
1,210,000
|
|
|
|
1,909,000
|
|
|
|
|
|
|
|
|
|
|
Total Assets:
|
|
|
9,482,000
|
|
|
|
12,356,000
|
|
55
|
|
|
|
|
|
|
|
|
Tax Liabilities:
|
|
|
|
|
|
|
|
|
Unrealized gains on AFS securities
|
|
|
(112,000
|
)
|
|
|
(12,000
|
)
|
NOLs credits, and other carryforward items
|
|
|
(79,000
|
)
|
|
|
8,000
|
|
|
|
|
|
|
|
|
|
|
Total Liabilities:
|
|
|
(191,000
|
)
|
|
|
(4,000
|
)
|
Less: Valuation Allowance
|
|
|
(1,634,000
|
)
|
|
|
(2,316,000
|
)
|
|
|
|
|
|
|
|
|
|
Net Deferred Tax Asset
|
|
$
|
7,657,000
|
|
|
$
|
10,036,000
|
|
|
|
|
|
|
|
|
|
|
A valuation allowance covering the deferred tax assets of the Company for November 30, 2018 and
November 30, 2017, has been provided as the Company does not believe it is more likely than not that all of the future income tax benefits will be realized. The valuation allowance changed by approximately ($711,000) and ($73,000) during the
years ended November 30, 2018 and 2017, respectively. The change for year ended November 30, 2017 was primarily capital loss carryovers expiring unused. The change for year ended November 30, 2018 was a result of the revaluation
impact of the Tax Cuts and Jobs Act of 2017 which reduced the federal tax rate from 34% to 21%.
The Company evaluates the recoverability
of our deferred tax assets as of the end of each quarter, weighing all positive and negative evidence, and are required to establish and maintain a valuation allowance for these assets if we determine that it is more likely than not that some or all
of the deferred tax assets will not be realized. The weight given to the evidence is commensurate with the extent to which the evidence can be objectively verified. If negative evidence exists, positive evidence is necessary to support a conclusion
that a valuation allowance is not needed.
The positive evidence that weighed in favor of releasing the allowance as of November 30,
2017 and ultimately outweighed the negative evidence against releasing the allowance was the following:
|
|
|
Identifiable sources of future income relating to the Companys deferred revenue accounts;
|
|
|
|
Certainty as to the amount available of deferred tax assets and nature in which the deferred tax assets reverse;
|
|
|
|
Profitability for years ended November 30, 2015 and 2016 and our expectations regarding the sustainability
of these profits;
|
|
|
|
The Companys three-year cumulative position as of November 30, 2017; and
|
|
|
|
The Companys taxable income projection for fiscal years ending November 30, 2018, 2019 and 2020.
|
The Tax Cuts and Jobs Act (the Tax Act) was signed into law on December 22, 2017. The Tax Act makes
significant changes to provision of the Internal Revenue Code, including changing the corporate tax rate to a flat 21% rate as of January 1, 2018. This requires the Companys net deferred tax assets and liabilities to be revalued at the
newly enacted U.S. corporate rate. The impact will be recognized in tax expense in the year of enactment. Based on evaluation, the Companys discrete expense for the rate impact will be approximately $3.1 million. Based on the
Companys evaluation, the Tax Act is not expected to impact the recoverability of its deferred tax asset.
A reconciliation of the
income tax provision with the amount of tax computed by applying the federal statutory rate to pretax income follows:
56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended November 30
|
|
|
|
|
|
|
2018
|
|
|
%
|
|
|
2017
|
|
|
%
|
|
Tax at Federal Statutory Rate
|
|
|
799,507
|
|
|
|
22.10
|
|
|
|
1,195,183
|
|
|
|
34.0
|
|
State Income Tax Effect
|
|
|
216,608
|
|
|
|
5.99
|
|
|
|
178,645
|
|
|
|
5.08
|
|
Valuation Allowance Release
|
|
|
|
|
|
|
0.00
|
|
|
|
|
|
|
|
0.00
|
|
Tax Compensation Differences
|
|
|
260,845
|
|
|
|
7.21
|
|
|
|
|
|
|
|
0.00
|
|
Permanent Disallowances
|
|
|
149,141
|
|
|
|
4.12
|
|
|
|
158,780
|
|
|
|
4.52
|
|
Impact of Tax Reform
|
|
|
3,078,094
|
|
|
|
85.08
|
|
|
|
|
|
|
|
0.00
|
|
Deferred Repricing
|
|
|
(28,337
|
)
|
|
|
(0.78
|
)
|
|
|
(342,645
|
)
|
|
|
(9.75
|
)
|
Other
|
|
|
(3,354
|
)
|
|
|
(0.09
|
)
|
|
|
118,640
|
|
|
|
3.37
|
|
Foreign tax credits
|
|
|
(108,314
|
)
|
|
|
(2.99
|
)
|
|
|
(108,481
|
)
|
|
|
(3.09
|
)
|
Foreign tax withholding
|
|
|
108,314
|
|
|
|
2.99
|
|
|
|
108,481
|
|
|
|
3.09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income taxes
|
|
$
|
4,472,504
|
|
|
|
123.63
|
|
|
$
|
1,308,603
|
|
|
|
37.22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company adopted the accounting standard for uncertain tax positions, ASC
740-10,
on December 1, 2007. As required by the standard, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely
than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being
realized upon ultimate settlement with the relevant tax authority. Increases or decreases to the unrecognized tax benefits could result from managements belief that a position can or cannot be sustained upon examination based on subsequent
information or potential lapse of the applicable statute of limitation for certain tax positions. There were no uncertain tax positions as of November 30, 2018 and 2017.
The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. For the years ended November 30,
2018 and 2017, the Company had no material provisions for interest or penalties related to uncertain tax positions.
The Company or one of
its subsidiaries files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions. The table below summarizes the open tax years and ongoing tax examinations in major jurisdictions as of November 30, 2018:
|
|
|
|
|
|
|
|
|
Jurisdiction
|
|
Open Tax Years
|
|
|
Examinations in
Process
|
|
United States Federal Income Tax
|
|
|
2013 - 2017
|
|
|
|
N/A
|
|
United States Various States
|
|
|
2012 - 2017
|
|
|
|
N/A
|
|
57
NOTE 11 STOCKHOLDERS EQUITY.
Common Stock Issuances
During the year
ended November 30, 2018, the Company issued 63,750 common shares to option holders who exercised options for $170,925. During the year ended November 30, 2017, the Company issued 33,031 common shares to option holders who exercised options
for $64,696.
Employee Stock Incentive Plan
The Company maintains the 2006 Stock Incentive Plan (the 2006 Plan) under which it has reserved 1,000,000 shares of the
Companys common stock for issuance pursuant to stock options, restricted stock, stock-appreciation rights (commonly referred to as SARs) and stock awards (i.e. performance options to purchase shares and performance units). As of
November 30, 2018, and November 30, 2017, there were 380,000 and 457,250 options issued, but not yet exercised, under the 2006 Plan, respectively. As of November 30, 2018, there were 0 shares available for future issuance under the
2006 Plan.
The Company maintains the 2012 Equity Incentive Plan (the 2012 Plan) which became effective December 1, 2011
as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting on July 10, 2012. The 2012 Plan originally reserved 1,500,000 shares of the Companys common stock for issuance pursuant to stock options,
restricted stock, SARs, and other stock awards (i.e. performance shares and performance units). In May 2012, the Board of Directors approved an amendment to the 2012 Plan to increase the number of shares of the Companys common stock reserved
for issuance to 2,500,000 shares. As of November 30, 2018, there were 621,365 service-based options issued, 129,729 service-based restricted common shares granted, 823,415 performance-based and 116,240 market-based restricted common shares
granted under the 2012 Plan. As of November 30, 2017, there were 569,729 service-based options issued, 129,729 service-based restricted common shares granted, 825,221 performance-based and 116,240 market-based restricted common shares granted
under the 2012 Plan. As of November 30, 2018, there were 0 shares available for future issuance under the 2012 Plan. In March 2018, the Company received notice that shares of the Companys common stock issued to certain executive officers
pursuant to the Companys 2012 Stock Incentive Plan had purportedly been issued in excess of the shares reserved for issuance under the Plan. The Company has established an independent committee of the Board of Directors to review this issue.
Service-based vesting condition options
The fair value of each option award is estimated on the date of the grant using the Black-Scholes valuation model that uses the assumptions
noted in the following table. Expected volatility is based on the historical volatility of the Companys stock over the most recent period commensurate with the expected life of the Companys stock options. The Company uses historical data
to estimate option exercise and employee termination within the valuation model. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected term of
options granted to employees is calculated, in accordance with the simplified method for plain vanilla stock options allowed under GAAP. Expected dividends are based on the historical trend of the Company not issuing
dividends.
Variables used to determine the fair value of the options granted for the years ended November 30, 2018 and
November 30, 2017 are as follows:
|
|
|
|
|
|
|
|
|
|
|
2018
|
|
|
2017
|
|
Weighted average values:
|
|
|
|
|
|
|
|
|
Expected dividends
|
|
|
0
|
%
|
|
|
0
|
%
|
Expected volatility
|
|
|
50.85
|
%
|
|
|
52.07
|
%
|
Risk free interest rate
|
|
|
2.67
|
%
|
|
|
1.82
|
%
|
Expected life
|
|
|
5.0 years
|
|
|
|
5.0 years
|
|
58
Stock option activity for options with only service-based vesting conditions for the year ended
November 30, 2018, was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
Weighted
Average
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
Remaining
|
|
|
Aggregate
|
|
|
|
Options
|
|
|
Exercise
Price
|
|
|
Contractual
Term (Years)
|
|
|
Intrinsic
Value
|
|
Outstanding at November 30, 2017
|
|
|
1,026,979
|
|
|
$
|
2.50
|
|
|
|
4.48
|
|
|
$
|
5,706,107
|
|
Granted
|
|
|
51,636
|
|
|
|
7.85
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(63,750
|
)
|
|
|
2.68
|
|
|
|
|
|
|
|
343,935
|
|
Expired/forfeited
|
|
|
(13,500
|
)
|
|
|
2.18
|
|
|
|
|
|
|
|
69,450
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at November 30, 2018
|
|
|
1,001,365
|
|
|
|
2.77
|
|
|
|
3.97
|
|
|
$
|
4,580,967
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at November 30, 2018
|
|
|
961,111
|
|
|
|
2.58
|
|
|
|
3.93
|
|
|
$
|
4,562,016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The weighted average grant date fair value of options granted during the years ended November 30, 2018
and November 30, 2017 was $3.23 and $3.23, respectively.
The aggregate intrinsic value represents the total value of the difference
between the Companys closing stock price on the last trading day of the period and the exercise price of the options, multiplied by the number of
in-the-money
stock options that would have been received by the option holders had all option holders exercised their options on either November 30, 2018 or November 30, 2017, as applicable. The intrinsic value of the Companys stock options
changes based on the closing price of the Companys stock.
Significant option groups outstanding and exercisable at
November 30, 2018 and related price and contractual life information are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding
|
|
|
Exercisable
|
|
Range of Exercise Prices
|
|
Outstanding
|
|
|
Weighted
Average
Remaining
Contractual
Life
(Years)
|
|
|
Weighted
Average
Exercise Price
|
|
|
Outstanding
|
|
|
Weighted
Average
Exercise Price
|
|
$1.01 to $2.00
|
|
|
422,500
|
|
|
|
2.93
|
|
|
$
|
1.73
|
|
|
|
422,500
|
|
|
$
|
1.73
|
|
$2.01 to $3.00
|
|
|
275,000
|
|
|
|
2.32
|
|
|
$
|
2.70
|
|
|
|
275,000
|
|
|
$
|
2.70
|
|
$3.01 to $4.00
|
|
|
227,229
|
|
|
|
7.17
|
|
|
$
|
3.18
|
|
|
|
223,062
|
|
|
$
|
3.18
|
|
$6.01 to $7.00
|
|
|
25,000
|
|
|
|
8.34
|
|
|
$
|
6.95
|
|
|
|
23,334
|
|
|
$
|
6.98
|
|
$7.01 to $8.00
|
|
|
51,636
|
|
|
|
5.08
|
|
|
$
|
7.85
|
|
|
|
17,215
|
|
|
$
|
7.85
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,001,365
|
|
|
|
3.97
|
|
|
$
|
2.77
|
|
|
|
961,111
|
|
|
$
|
2.58
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A summary of the status of the Companys
non-vested
options as of
November 30, 2018, and changes during the fiscal year then ended, is presented below:
59
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
|
|
|
|
Grant-Date
|
|
|
|
Options
|
|
|
Fair Value
|
|
Non-vested
at November 30, 2017
|
|
|
39,168
|
|
|
$
|
2.41
|
|
Granted
|
|
|
51,636
|
|
|
|
3.23
|
|
Vested
|
|
|
(50,550
|
)
|
|
|
2.73
|
|
Forfeited
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-vested
at November 30, 2017
|
|
|
40,254
|
|
|
$
|
3.06
|
|
|
|
|
|
|
|
|
|
|
As of November 30, 2018, there was approximately $98,000 of total unrecognized compensation cost related
to
non-vested
share-based compensation arrangements granted under the 2006 Plan and the 2012 Plan. The cost is expected to be recognized over a weighted-average period of 1.01 years as of November 30,
2018. The total fair value of options vested during the fiscal year ended November 30, 2018 was approximately $138,000.
Performance and
market-based vesting condition options
Per the 2018 Employment Agreements, based upon certain performance criteria, the Company shall
grant David Portnoy and Mark Portnoy a percentage of up to 47,273 and 40,000, respectively, of qualified stock options of the Companys common stock. For market-based vesting condition options, accounting principles do not require that the
market condition be met in order for the compensation cost to be recognized. Fair value of these options has been determined using a Monte Carlo valuation approach and is being recognized over the requisite service period, regardless if the market
condition will be met. During fiscal 2018, 15,756 and 13,332, respectively, of qualified stock options were forfeited as certain market conditions were not met by the end of the requisite service period. The fair value of these options as of
November 30, 2018 was approximately $144,300 and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss). For performance-based vesting condition options, the
Company estimated the fair value of the qualified stock options that met certain performance targets by the end of the requisite service period using a Black-Scholes valuation model. The estimated fair value of 15,756 and 13,332 of qualified stock
options, respectively, was approximately $95,000 and is reflected as selling, general and administrative expenses in the accompanying consolidated statement of comprehensive income (loss).
Per the Amendment Agreement, based upon certain performance criteria, the Company shall grant Oleg Mikulinsky a percentage of up to 8,000 of
qualified stock options of the Companys common stock. For market-based vesting condition options, accounting principles do not require that the market condition be met in order for the compensation cost to be recognized. Fair value of these
options has been determined using a Monte Carlo valuation approach and is being recognized over the requisite service period, regardless if the market condition will be met. During fiscal 2018, 2,666, of qualified stock options were forfeited as
certain market conditions were not met by the end of the requisite service period. The fair value of these options as of November 30, 2018 was approximately $13,500 and is reflected as selling, general and administrative expenses in the
accompanying consolidated statement of comprehensive income (loss). For performance-based vesting condition options, the Company estimated the fair value of the qualified stock options that met certain performance targets by the end of the requisite
service period using a Black-Scholes valuation model. The estimated fair value of 2,666 of qualified stock options was approximately $9,300 and is reflected as selling, general and administrative expenses in the accompanying consolidated statement
of comprehensive income (loss).
As of November 30, 2017, there were no performance or market-based vesting condition options granted
or outstanding.
60
Restricted common shares
As of April 15, 2016, the Company entered into Amended and Restated Employment Agreements (Employment Agreements) with each of
the Companys
Co-CEOs.
The Employment Agreements provide for the grant of shares of the Companys common stock based on certain performance measures being attained by each of the Companys
Co-CEOs
during fiscal year 2016 and fiscal year 2017. The Employment Agreements state if David Portnoy and Mark Portnoy are employed by the Company on November 30, 2016 and November 30, 2017, then no later
than February 28, 2017 and February 28, 2018, respectively, the Company will grant up to 186,487 and 162,163 shares of common stock for each fiscal year. Based upon the performance measures attained as of November 30, 2016, the
Company granted 183,145 and 159,257 shares of common stock to David Portnoy and Mark Portnoy, respectively. There was $0 of total unrecognized compensation cost as of November 30, 2018 and November 30, 2017, respectively. Based upon the
performance measures being attained as of November 30, 2017, David Portnoy and Mark Portnoy earned a total of 121,801 and 105,915 shares of common stock, respectively. Pursuant to the terms of the Employment Agreements, the
Co-CEOs
each opted to receive a lump sum cash payment in lieu of 30,000 shares of earned common stock which amounted to approximately $444,000. The Company then granted the remaining earned shares of 91,801 and
75,915 to David Portnoy and Mark Portnoy, respectively. The fair value of the shares granted was approximately $756,000. There was $0 and $496,000 of total unrecognized compensation cost as of November 30, 2018 and November 30, 2017,
respectively.
As of April 18, 2016, the Company entered into a second Amendment Agreement (the Amendment), with the
Companys CIO Oleg Mikulinsky effective December 1, 2015, amending certain terms of the Amendment Agreement dated May 1, 2013 and Mikulinsky Employment Agreement dated March 5, 2012. The Amendment provides for the grant of shares
of the Companys common stock based on certain performance measures being attained by the Company during fiscal year 2016 and fiscal year 2017. The Amendment states if Executive is employed by the Company on November 30, 2016 and
November 30, 2017, then no later than February 28, 2017 and February 28, 2018, respectively, the Company will grant Executive up to 20,000 shares of restricted stock based on performance as set forth in the Amendment per each fiscal
year. Based upon performance measures being attained as of November 30, 2016, the Company granted 19,620 shares of common stock to Oleg Mikulinksy. There was $0 of total unrecognized compensation cost as of November 30, 2018 and
November 30, 2017, respectively. Based upon performance measures being attained as of November 30, 2017, the Company will grant a total of 14,729 shares of common stock to Oleg Mikulinksy. The fair value of the shares to be granted is
approximately $80,000. There was $0 and $40,000 of total unrecognized compensation cost as of November 30, 2018 and November 30, 2017, respectively.
NOTE 12LICENSE AGREEMENTS
The
Company enters into two types of licensing agreements and in both types, the Company earns revenue on the initial license fees. Under the technology agreements, the Company earns processing and storage royalties from the affiliates that process in
their own facility. Under the marketing agreements, the Company earns processing and storage revenues from affiliates that store specimens in the Companys facility in Oldsmar, Florida.
Technology Agreements
The Company has
entered into a definitive License and Royalty Agreement with LifeCell International Private Limited, formerly Asia Cryo-Cell Private Limited, (LifeCell) to establish and market its umbilical cord blood and menstrual stem cell programs in
India.
61
Per the License and Royalty Agreement with Lifecell, there is a $1,000,000 cap on the amount of
royalties due to the Company per year and a $10,000,000 cap on the amount of royalties due to the Company for the term of the License and Royalty Agreement. The cap(s) are calculated based on Lifecells fiscal year end, March 31
st
. As of the end of the Companys fiscal years ended November 30, 2018 and November 30, 2017, Lifecell had reached the $1,000,000 cap and paid the Company in full for Lifecells
fiscal year ended March 31, 2018 and March 31, 2017, respectively. Since inception of the License and Royalty Agreement, the Company has recorded $7,000,000 in royalty income due under the terms of the License and Royalty Agreement, of
which, Lifecell has paid the Company $6,500,000 as of November 30, 2018. The balance of $500,000 is reflected as Accounts Receivable on the accompanying consolidated balance sheets.
The following table details the processing and storage royalties earned for the technology agreements for fiscal years 2018 and 2017. The
initial license fees and processing and storage royalties are reflected in licensee income in the accompanying consolidated statements of comprehensive income (loss).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the years ended November 30,
|
|
|
|
2018
|
|
|
2017
|
|
|
|
License
Fee
|
|
|
Processing
and Storage
Royalties
|
|
|
Total
|
|
|
License
Fee
|
|
|
Processing
and Storage
Royalties
|
|
|
Total
|
|
India
|
|
|
|
|
|
|
1,000,000
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
1,003,056
|
|
|
|
1,003,056
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
|
|
|
$
|
1,000,000
|
|
|
$
|
1,000,000
|
|
|
$
|
|
|
|
$
|
1,003,056
|
|
|
$
|
1,003,056
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketing Agreements
The Company has definitive license agreements to market the Companys umbilical cord blood stem cell programs in Costa Rica, El Salvador,
Guatemala, Honduras, Nicaragua, Panama and Pakistan.
NOTE 13 COMMITMENTS AND CONTINGENCIES
Employment Agreements
The Company has
employment agreements in place for certain members of management. These employment agreements which include severance arrangements, are for periods ranging from one to two years and contain certain provisions for severance payments in the event of
termination or change of control.
Leases
The Company entered into a
ten-year
lease in April 2004 for its
17,600-square
foot cGMP/cGTP compliant corporate headquarters in Oldsmar, Florida. This facility contains the Companys executive offices, its conference and training center, its laboratory processing and
cryogenic storage facility and its scientific offices. In July 2018, the Company extended the main lease through December 31, 2021 for the 17,600 square foot space.
The Company entered into a
one-year
lease in November 2013 for an additional 800 square feet of office
space in Miami, Florida for annual rent of approximately $38,000. The lease commenced during December 2013. In December 2016, the Company extended the lease through December 31, 2018.
62
Rent charged to operations was $312,307 and $310,970 for the fiscal years ended November 30,
2018 and 2017, respectively, and is included in cost of sales and selling, general and administrative expenses in the consolidated statements of comprehensive income (loss).
The future minimum rental payments under the operating lease are as follows:
|
|
|
|
|
Fiscal Year Ending November 30,
|
|
Rent
|
|
2019
|
|
$
|
227,368
|
|
2020
|
|
$
|
225,984
|
|
2021
|
|
$
|
225,984
|
|
2022
|
|
$
|
18,832
|
|
Legal Proceedings
On December 3, 2015, a complaint styled
Gary T. Brotherson, M.D., et al. v. Cryo-Cell International, Inc.,
Case No.
15-007461-CI,
Circuit Court, Sixth Judicial Circuit, Pinellas County, Florida, was served on the Company, naming it as defendant and alleging, among other things, that the
Company breached certain agreements with plaintiffs and seeking damages in excess of $15,000, the jurisdictional amount of the court in which the action is pending. On January 12, 2016, the Company served its answer, affirmative defenses, and
counterclaim against the plaintiffs. The Company believes the plaintiffs claims are without merit and it intends to contest the action vigorously. At this time, it is not possible for the Company to estimate the loss or the range of possible
loss in the event of an unfavorable outcome, as the ultimate resolution of the complaint is uncertain at this time. No amounts have been accrued as of November 30, 2018.
In addition, from time to time the Company is subject to proceedings, lawsuits, contract disputes and other claims in the normal course of its
business. The Company believes that the ultimate resolution of current matters should not have a material adverse effect on the Companys business, consolidated financial position or results of operations. It is possible, however, that there
could be an unfavorable ultimate outcome for or resolution which could be material to the Companys results of operations for a particular quarterly reporting period. Litigation is inherently uncertain and there can be no assurance that the
Company will prevail. The Company does not include an estimate of legal fees and other related defense costs in its estimate of loss contingencies.
NOTE 14 RETIREMENT PLAN
The
Company maintains a 401(k)-retirement plan (the 401(k) Plan), which allows eligible employees to defer up to 15% of their eligible compensation. In fiscal 2008, the Company implemented an employer match up to certain limits. In fiscal
2010, the Company implemented a Safe Harbor provision with matching contributions up to certain limits. For the years ended November 30, 2018 and November 30, 2017, the Company made matching contributions of approximately $158,000 and
$141,000, respectively, to the 401(k) Plan.
NOTE 15 REVENUE SHARING AGREEMENTS (RSAs)
Florida
. On February 9, 1999, the previous agreements with the Companys Arizona Revenue Sharing investors were modified and replaced
by a RSA for the state of Florida for a price of $1,000,000. The revenue sharing agreement applies to net storage revenues originating from specimens from within the state of Florida. The revenue sharing agreement entitles the investors to revenues
of up to a maximum of 33,000 storage spaces.
63
Illinois
. In 1996, the Company signed agreements with a group of investors entitling them to an
on-going
50% share of the Companys 75% share of the annual storage fees (net storage revenues) less a deduction for 50% of billing and collection expenses generated by specimens stored in the
Illinois Masonic Medical Center for a price of $1,000,000. The agreements were modified in 1998 to broaden the covered specimens to those originating in Illinois and its contiguous states and stored in Oldsmar, Florida for a maximum of up to 33,000
storage spaces.
Texas
. On May 31, 2001, the Company entered into an RSA with Red Rock Partners, an Arizona general partnership,
entitling them to
on-going
shares in a portion of the Companys net storage revenue generated by specimens originating from within the State of Texas for a price of $750,000. The investors are entitled to
a 37.5% share of net storage revenues originating in the State of Texas to a maximum of 33,000 storage spaces. During fiscal 2008, Red Rock assigned 50% of their interest in the agreement to SCC Investments, Inc., an Arizona corporation. During
fiscal year 2010, SCC Investments, Inc. assigned its interest to SCF Holdings, LLC, an Arizona limited liability company.
The Company
made total payments to all RSA holders of $671,245 and $589,399 for the fiscal years ended November 30, 2018 and 2017, respectively. The Company recorded an RSA accrual of $798,292 and $616,990 as of November 30, 2018 and 2017,
respectively, related to interest owed to the RSA holders, which is included in accrued expenses in the Companys consolidated financial statements under Item 8 of this Annual Report on Form
10-K.
The
Company also recorded interest expense of $848,024 and $730,778 for the fiscal years ended November 30, 2018 and 2017, respectively, which is reflected in interest expense on the accompanying consolidated statements of comprehensive (loss)
income.
NOTE 16 SHARE REPURCHASE PLAN
In December 2011, the Companys Board of Directors authorized management at its discretion to repurchase up to one million (1,000,000)
shares of the Companys outstanding common stock. On June 6, 2012, the Board of Directors of the Company increased the number of shares of the Companys outstanding common stock that management is authorized to repurchase to up to
three million (3,000,000). On April 8, 2015, the Board of Directors of the Company increased the number of shares of the Companys outstanding common stock that management is authorized to repurchase to up to six million (6,000,000)
shares. On October 6, 2016, the Board of Directors of the Company increased the number of shares of the Companys outstanding common stock that management is authorized to repurchase to up to eight million (8,000,000) shares. The
repurchases must be effectuated through open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule
10b5-1
of the Securities and Exchange Commission or in such other manner as will comply with the provisions of the Securities Exchange Act of 1934.
As of November 30, 2018, the Company had repurchased an aggregate of 5,801,086 shares of the Companys common stock at an average
price of $3.37 per share through open market and privately negotiated transactions. The Company purchased 0 and 86,915 shares of the Companys common stock during the twelve months ended November 30, 2018 and November 30, 2017,
respectively, at an average price of $0.00 per share and $5.14 per share, respectively.
The repurchased shares are held as treasury stock
at cost and have been removed from common shares outstanding as of November 30, 2018 and November 30, 2017. As of November 30, 2018, and November 30, 2017, 5,801,086 and 5,801,086 shares, respectively, were held as treasury
stock.
64
Subsequent to the balance sheet date, the Company has not repurchased any additional shares of
the Companys common stock.
NOTE 17 RELATED PARTY TRANSACTIONS
David Portnoy, the Companys Chairman and
Co-Chief
Executive officer, is the brother of the
Companys
Co-Chief
Executive Officer Mark Portnoy. The Companys Audit Committee Chairman, Harold Berger, provides accounting services to the Companys
Co-Chief
Executive Officer Mark Portnoy and to PartnerCommunity, Inc. The Companys Chairman and
Co-Chief
Executive Officer, David Portnoy, serves as the Chairman
of the Board of PartnerCommunity, Inc.